Challenges in Ototoxicity Monitoring in the pediatric oncology population

Journal of the American Academy of Audiology

Volumn 25, Issue 8, 2014, Pages 760-774

  Bass, Johnnie K ^a,b   Bhagat, Shaum P ^a,b  

^a UNIVERSITY OF MEMPHIS   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cancer; Carboplatin; Child; Cisplatin; Hearing loss; Otoacoustic emissions; Ototoxicity; Radiation

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT;

ARTICLE; AUDIOLOGIST; CANCER RADIOTHERAPY; CHILD; CHILDHOOD CANCER; DISEASE SEVERITY; EDUCATION; HEARING; HEARING IMPAIRMENT; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ONCOLOGIST; OTOTOXICITY; PATIENT MONITORING; SOCIAL ASPECT; ADVERSE EFFECTS; AUDIOLOGY; EARLY DIAGNOSIS; HEARING LOSS; MEDICAL EDUCATION; NEOPLASMS; PROCEDURES; SKULL IRRADIATION;

ANTINEOPLASTIC AGENTS; AUDIOLOGY; CHILD; CRANIAL IRRADIATION; EARLY DIAGNOSIS; EDUCATION, MEDICAL, GRADUATE; HEARING LOSS; HUMANS; NEOPLASMS; PLATINUM COMPOUNDS;

EID: 84908613421     PISSN: 10500545     EISSN: 21573107     Source Type: Journal    
DOI: 10.3766/jaaa.25.8.6     Document Type: Article

References (81)

1. American Academy of Audiology. (2009) Ototoxicity Monitoring. http://www.audiology.org/resources/documentlibrary/Documents/OtoMonGuidelines.pdf
2. American Speech-Language-Hearing Association. (1994) Audiologic management of individuals receiving cochleotoxic drug therapy guidelines. http://www.asha.org/policy/GL1994-00003.htm
3. Bass JK, Huang J, Onar-Thomas A, et al. (2014) Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treatment with cisplatin for medulloblastoma. Pediatr Blood Cancer 61(4):601-605.
4. Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. (1981) Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report. Cancer Treat Rep 65(9-10):815-822.
5. Bertolini P, Lassalle M, Mercier G, et al. (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26(10):649-655.
6. Bess FH, Dodd-Murphy J, Parker RA. (1998) Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 19(5):339-354.
7. Bhagat S, Bass J, Qaddoumi I, et al. (2013) Time-frequency analysis of transient-evoked otoacoustic emissions in children exposed to carboplatin chemotherapy. Audiol Neurootol 18(2):71-82.
8. Bhagat SP, Bass JK, White ST, et al. (2010) Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma. Int J Pediatr Otorhinolaryngol 74(10):1156-1163.
9. Bhandare N, Antonelli PJ, Morris CG, Malayapa RS, Mendenhall WM. (2007) Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 67(2):469-479.
10. Bhandare N, Jackson A, Eisbruch A, et al. (2010) Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 76(3, Suppl): S50-S57.
11. Bohne BA, Marks JE, Glasgow GP. (1985) Delayed effects of ionizing radiation on the ear. Laryngoscope 95(7 Pt 1):818-828.
12. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. (1991) Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19(4):295-300.
13. Brock P, Knight K, Freyer DR, et al. (2012) Platinum-based ototoxicity in children: a consensus reviewonmechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 30(19):2408-2417.
14. Buck TP, Trahan HP, Wendel OT. (2007) Pharmacotherapeutics and patient factors. In: Campbell KCM, ed. Pharmacology and Ototoxicity for Audiologists. Independence, KY: Cengage Learning, 19-32.
15. Chang KW, Chinosornvatana N. (2010) Practical grading system for evaluating cisplatin ototoxicity in children. J ClinOncol 28(10):1788-1795.
16. Chen WC, Jackson A, Budnick AS, et al. (2006) Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 106(4):820-829.
17. Comis SD, Rhys-Evans PH, Osborne MP, Pickles JO, Jeffries DJ, Pearse HA. (1986) Early morphological and chemical changes induced by cisplatin in the guinea pig organ of Corti. J Laryngol Otol 100(12):1375-1383.
18. Conklin HM, Li C, Xiong X, Ogg RJ, Merchant TE. (2008) Predicting change in academic abilities after conformal radiation therapy for localized ependymoma. J Clin Oncol 26(24):3965-3970.
19. Davis JM, Elfenbein J, Schum R, Bentler RA. (1986) Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. J Speech Hear Disord 51(1):53-62.
20. Dhooge I, Dhooge C, Geukens S, De Clerck B, De Vel E, Vinck BM. (2006) Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives. Int J Audiol 45(6):337-343.
21. Downs MP, Yoshinaga-Itano C. (1999) The efficacy of early identification and intervention for children with hearing impairment. Pediatr Clin North Am 46(1):79-87.
22. Einarsson EJ, Petersen H, Wiebe T, et al. (2010) Long term hearing degeneration after platinum-based chemotherapy in childhood. Int J Audiol 49(10):765-771.
23. Fong RS, Beste DJ, Murray KJ. (1995) Pediatric sensorineural hearing loss after temporal bone radiation. Am J Otol 16(6): 793-796.
24. Friedman DL, Himelstein B, Shields CL, et al. (2000) Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 18(1):12-17.
25. Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. (2010) Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics 125(4):e938-e950.
26. Gurney JG, Bass JK. (2012) New International Society of Pediatric Oncology Boston Ototoxicity Grading Scale for pediatric oncology: still room for improvement. J Clin Oncol 30(19):2303-2306.
27. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML; Children's Oncology Group. (2007) Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics 120(5):e1229-e1236.
28. Higby DJ, Wallace HJ, Jr, Albert D, Holland JF. (1974) Diamminodichloroplatinum in the chemotherapy of testicular tumors. J Urol 112(1):100-104.
29. Hinojosa R, Riggs LC, Strauss M, Matz GJ. (1995) Temporal bone histopathology of cisplatin ototoxicity. Am J Otol 16(6):731-740.
30. Ho WK, Wei WI, Kwong DL, et al. (1999) Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study. Head Neck 21(6):547-553.
31. Hua C, Bass JK, Khan R, Kun LE, Merchant TE. (2008) Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys 72(3):892-899.
32. Huang E, Teh BS, Strother DR, et al. (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52(3):599-605.
33. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. (2009) Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 52(5):637-643.
34. Jereczek-Fossa BA, Zarowski A, Milani F, Orecchia R. (2003) Radiotherapy-induced ear toxicity. Cancer Treat Rev 29(5):417-430.
35. Jonathan EC, Bernhard EJ, McKenna WG. (1999) How does radiation kill cells? Curr Opin Chem Biol 3(1):77-83.
36. Kelland L. (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573-584.
37. Khuntia D, Tomé WA, Mehta MP. (2009) Radiation techniques in neuro-oncology. Neurotherapeutics 6(3):487-499.
38. Kirsch DG, Tarbell NJ. (2004) Conformal radiation therapy for childhood CNS tumors. Oncologist 9(4):442-450.
39. Knight KR, Kraemer DF, Neuwelt EA. (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23(34):8588-8596.
40. Knight KR, Kraemer DF, Winter C, Neuwelt EA. (2007) Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25(10):1190-1195.
41. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cisdiamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46(4 Pt 2):1972-1979.
42. Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. (2006) Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107(2):417-422.
43. Lambert MP, Shields C, Meadows AT. (2008) A retrospective review of hearing in childrenwith retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 50(2):223-226.
44. Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE. (2009) Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 52(3):387-391.
45. Li Y, Womer RB, Silber JH. (2004) Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 40(16):2445-2451.
46. Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DY. (2006) Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 24(12):1904-1909.
47. McHaney VA, Thibadoux G, Hayes FA, Green AA. (1983) Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 102(2): 314-317.
48. Meech RP, Campbell KC, Hughes LP, Rybak LP. (1998) A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis. Hear Res 124(1-2):44-59.
49. Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X. (2009) Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol 27(22):3691-3697.
50. Merchant TE, Gould CJ, Xiong X, et al. (2004) Early neurootologic effects of three-dimensional irradiation in children with primary brain tumors. Int J Radiat Oncol Biol Phys 58(4):1194-1207.
51. Merchant TE, Pollack IF, Loeffler JS. (2010) Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol 20(1):58-66.
52. Moeller BJ, Chintagumpala M, Philip JJ, et al. (2011) Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol 6:58.
53. Moleti A, Sisto R, Tognola G, Parazzini M, Ravazzani P, Grandori F. (2005) Otoacoustic emission latency, cochlear tuning, and hearing functionality in neonates. J Acoust Soc Am 118(3 Pt 1):1576-1584.
54. National Cancer Institute. (2003) Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/protocol-Development/electronic-applications/docs/ctcaev3.pdf
55. National Cancer Institute. (2010) Common Terminology Criteria for Adverse Events, Version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdff
56. Neuwelt EA, Brock P. (2010) Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 28(10):1630-1632.
57. Nitschke R, Starling KA, Vats T, Bryan H. (1978) Cis-diammine-dichloroplatinum (NSC-119875) in childhood malignancies: a Southwest Oncology Group study. Med Pediatr Oncol 4(2):127-132.
58. Pan CC, Eisbruch A, Lee JS, Snorrason RM, Ten Haken RK, Kileny PR. (2005) Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 61(5):1393-1402.
59. Parsons SK, Neault MW, Lehmann LE, et al. (1998) Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22(7):669-674.
60. Polkinghorn WR, Dunkel IJ, Souweidane MM, et al. (2011) Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma. Int J Radiat Oncol Biol Phys 81(3):e15-e20.
61. Pratt CB, Hayes A, Green AA, et al. (1981) Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. Cancer Treat Rep 65(11-12):1021-1026.
62. Punnett A, Bliss B, Dupuis LL, Abdolell M, Doyle J, Sung L. (2004) Ototoxicity following pediatric hematopoietic stem cell transplantation: a prospective cohort study. Pediatr Blood Cancer 42(7):598-603.
63. Qaddoumi I, Bass JK, Wu J, et al. (2012) Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30(10):1034-1041.
64. Ruiz L, Gilden J, Jaffe N, Robertson R, Wang YM. (1989) Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis-diamminedichloroplatinum(II). Cancer Res 49(3):742-744.
65. Saito T, Saito H, Saito K, Wakui S, Manabe Y, Tsuda G. (1989) Ototoxicity of carboplatin in guinea pigs. Auris Nasus Larynx 16(1):13-21.
66. Schmidt CM, Knief A, Lagosch AK, Deuster D, am Zehnhoff-Dinnesen A. (2008) Left-right asymmetry in hearing loss following cisplatin therapy in children - the left ear is slightly but significantly more affected. Ear Hear 29(6):830-837.
67. Schweitzer VG, Hawkins JE, Lilly DJ, et al. (1984) Ototoxic and nephrotoxic effects of combined treatment with cis-diammine-dichloroplatinum and kanamycin in the guinea pig. Otolaryngol Head Neck Surg 92(1):38-49.
68. Siegel R, Naishadham D, Jemal A. (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11-30.
69. Smits C, Swen SJ, Theo Goverts S, Moll AC, Imhof SM, Schouten-van Meeteren AY. (2006) Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer 42(4): 492-500.
70. Steen RG, Mirro J, eds. (2000) Childhood Cancer: A Handbook from St. Jude Children's Research Hospital. Cambridge: Perseus.
71. Stelmachowicz PG, Pittman AL, Hoover BM, Lewis DE, Moeller MP. (2004) The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 130(5):556-562.
72. Stöhr W, Langer T, Kremers A, et al.; German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology. (2005) Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 23(3):201-207.
73. Tognola G, Grandori F, Avan P, Ravazzani P, Bonfils P. (1999) Frequency-specific information from click evoked otoacoustic emissions in noise-induced hearing loss. Audiology 38(5):243-250.
74. Tognola G, Grandori F, Ravazzani P. (1998) Wavelet analysis of click-evoked otoacoustic emissions. IEEE Trans Biomed Eng 45(6):686-697.
75. Wake M, Takeno S, Ibrahim D, Harrison R, Mount R. (1993) Carboplatin ototoxicity: an animal model. J Laryngol Otol 107(7):585-589.
76. Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J. (1991) Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 12(2):91-102.
77. Williams GB, Kun LE, Thompson JW, Gould HJ, Stocks RM. (2005) Hearing loss as a late complication of radiotherapy in children with brain tumors. Ann Otol Rhinol Laryngol 114(4):328-331.
78. Wright CG, Schaefer SD. (1982) Inner ear histopathology in patients treated with cis-platinum. Laryngoscope 92(12):1408-1413.
79. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. (2012) Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer 59(1):144-148.
80. Yoshinaga-Itano C. (1999) Benefits of early intervention for children with hearing loss. Otolaryngol Clin North Am 32(6): 1089-1102.
81. Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. (1998) Language of early- and later-identified children with hearing loss. Pediatrics 102(5):1161-1171.